NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 122 filers reported holding NURIX THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $776,875 | -32.1% | 98,839 | -13.7% | 0.01% | -16.7% |
| Q2 2023 | $1,143,735 | -8.1% | 114,488 | -18.3% | 0.01% | -25.0% |
| Q1 2023 | $1,244,505 | -31.3% | 140,147 | -15.1% | 0.01% | -46.7% |
| Q4 2022 | $1,812,567 | +6.2% | 165,079 | +26.1% | 0.02% | -16.7% |
| Q3 2022 | $1,706,000 | +89.6% | 130,909 | +84.3% | 0.02% | +125.0% |
| Q2 2022 | $900,000 | -56.1% | 71,049 | -51.4% | 0.01% | -33.3% |
| Q1 2022 | $2,049,000 | -22.0% | 146,280 | +61.3% | 0.01% | -14.3% |
| Q4 2021 | $2,626,000 | +48.9% | 90,706 | +54.1% | 0.01% | +16.7% |
| Q3 2021 | $1,764,000 | -15.5% | 58,866 | -25.2% | 0.01% | -7.7% |
| Q2 2021 | $2,088,000 | -1.0% | 78,690 | +16.0% | 0.01% | -7.1% |
| Q1 2021 | $2,109,000 | – | 67,827 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |